Literature DB >> 32463426

Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer-Reply.

George W Sledge1, Martin Frenzel2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32463426     DOI: 10.1001/jamaoncol.2020.1518

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  2 in total

1.  High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.

Authors:  Marta Palafox; Laia Monserrat; Meritxell Bellet; Guillermo Villacampa; Abel Gonzalez-Perez; Mafalda Oliveira; Fara Brasó-Maristany; Nusaibah Ibrahimi; Srinivasaraghavan Kannan; Leonardo Mina; Maria Teresa Herrera-Abreu; Andreu Òdena; Mònica Sánchez-Guixé; Marta Capelán; Analía Azaro; Alejandra Bruna; Olga Rodríguez; Marta Guzmán; Judit Grueso; Cristina Viaplana; Javier Hernández; Faye Su; Kui Lin; Robert B Clarke; Carlos Caldas; Joaquín Arribas; Stefan Michiels; Alicia García-Sanz; Nicholas C Turner; Aleix Prat; Paolo Nuciforo; Rodrigo Dienstmann; Chandra S Verma; Nuria Lopez-Bigas; Maurizio Scaltriti; Monica Arnedos; Cristina Saura; Violeta Serra
Journal:  Nat Commun       Date:  2022-09-07       Impact factor: 17.694

2.  Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study.

Authors:  Chien-Ting Liu; Meng-Che Hsieh; Yu-Li Su; Chaio-Ming Hung; Sung-Nan Pei; Chun-Kai Liao; Yu-Fen Tsai; Hsiu-Yun Liao; Wei-Ching Liu; Chong-Chi Chiu; Shih-Chung Wu; Shih-Ho Wang; Ching-Ting Wei; Kun-Ming Rau
Journal:  J Cancer       Date:  2021-07-03       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.